Other languages Alvotech

Equities

ALVO

LU2458332611

End-of-day quote Nasdaq Other stock markets 06:00:00 2024-06-03 pm EDT			5-day change	1st Jan Change
13.91 ^USD	-0.36%		-0.57%	+21.17%

May. 24	Barclays Adjusts Price Target on Alvotech to $22 From $20, Maintains Overweight Rating	MT
May. 22	Transcript : Alvotech, Q1 2024 Earnings Call, May 22, 2024

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Alvotech Raises Revenue Guidance for the Full Year 2024	May. 22
Alvotech Narrows Q1 Loss as Revenue Increases; Shares Head Higher Premarket	May. 22
Alvotech Narrows Q1 Loss as Revenue Increases	May. 22
Alvotech Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 21
Alvotech Signs Commercialization Deal for Prolia, Xgeva Biosimilar	May. 21
Alvotech and Dr. Reddy's Partner to Commercialize Biosimilar Candidate Denosumab	May. 21
Alvotech and Dr. Reddy's Enter into Collaboration for Commercialization of AVT03	May. 21
Teva Pharmaceutical Industries Limited and Alvotech Announce SIMLANDI® Injection Now Available in the U.S	May. 20
Le ultime operazioni dei gestori star	May. 20
Die jüngsten Transaktionen der Star-Fondsmanager	May. 18
De recentste transacties van de sterbeheerders	May. 18
Las últimas operaciones de los gestores estrella	May. 17
Les dernières transactions des gérants stars	May. 17
Alvotech to Manufacture Humira Biosimilar for Quallent Pharmaceuticals	Apr. 30
Alvotech to Make Humira Biosimilar Adalimumab-ryvk for Quallent	Apr. 30
Alvotech Announces U.S. Commercialization Agreement with Quallent to Drive Patient Savings with First High-Concentration Citrate-Free Interchangeable Biosimilar to Humira	Apr. 30
Cigna to offer Humira rivals with $0 copay at specialty pharmacy	Apr. 25
Alvotech’s Simponi Biosimilar Candidate Shows Efficacy in Confirmatory Study	Apr. 24
Alvotech Announces Topline Results from A Confirmatory Clinical Study for AVT05, A Proposed Biosimilar for Simponi	Apr. 24
Alvotech Signs U.S. Agreement to Expand Access for Newly Approved High-Concentration Interchangeable Biosimilar to Humira®	Apr. 19

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Alvotech

Equities

ALVO

LU2458332611

Other languages

Filters